REPLIMUNE GROUP, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
REPLIMUNE GROUP, INC. (REPL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 2.78% for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2023-02-09
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2020-12-31 was 0.31%, a 81.55% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2020-09-30 was 0.33%, a 80.36% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2020-06-30 was 1.24%, a 47.01% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2019-12-31 was 1.68%, a 40.64% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month |
|---|---|---|---|
| 2022-12-31 | 2.78% 10-Q · filed 2023-02-09 | ||
| 2022-09-30 | 2.61% 10-Q · filed 2022-11-03 | ||
| 2021-12-31 | 1.12% 10-Q · filed 2023-02-09 | ||
| 2021-09-30 | 1.11% 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | 0.31% 10-Q · filed 2021-02-04 | 1.01% 10-Q · filed 2022-02-03 | |
| 2020-09-30 | 0.33% 10-Q · filed 2020-11-05 | 1.08% 10-Q · filed 2021-11-04 | |
| 2020-06-30 | 1.24% 10-Q · filed 2020-08-07 | ||
| 2019-12-31 | 1.68% 10-Q · filed 2021-02-04 | 2.17% 10-Q · filed 2021-02-04 | |
| 2019-09-30 | 1.68% 10-Q · filed 2020-11-05 | 2.30% 10-Q · filed 2020-11-05 | |
| 2019-06-30 | 2.34% 10-Q · filed 2020-08-07 | ||
| 2018-12-31 | 2.83% 10-Q · filed 2020-02-13 | 2.83% 10-Q · filed 2020-02-13 | |
| 2018-09-30 | 2.83% 10-Q · filed 2019-11-12 | 2.83% 10-Q · filed 2019-11-12 | |
| 2017-12-31 | 2.06% 10-Q · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |